Fukuda Denshi Co Ltd
TSE:6960
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ovid Therapeutics Inc
NASDAQ:OVID
|
US |
|
Z
|
ZAZZ Energy of Sweden AB (publ)
STO:ZAZZ B
|
SE |
Fukuda Denshi Co Ltd
Total Liabilities
Fukuda Denshi Co Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Fukuda Denshi Co Ltd
TSE:6960
|
Total Liabilities
¥34.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
0%
|
|
|
Terumo Corp
TSE:4543
|
Total Liabilities
¥734.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Olympus Corp
TSE:7733
|
Total Liabilities
¥684.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
0%
|
|
|
Sysmex Corp
TSE:6869
|
Total Liabilities
¥197.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Nihon Kohden Corp
TSE:6849
|
Total Liabilities
¥74.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
JEOL Ltd
TSE:6951
|
Total Liabilities
¥84.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
0%
|
|
Fukuda Denshi Co Ltd
Glance View
Fukuda Denshi Co Ltd. is a stalwart in the medical technology arena, having carved out a niche as a leading provider of innovative medical devices and systems. Founded in the mid-20th century, the company has stayed true to its mission of enhancing global healthcare with cutting-edge solutions. Over the years, Fukuda Denshi has evolved its product range to encompass a wide array of essential medical equipment, including electrocardiographs, patient monitoring systems, and ultrasonic diagnosis devices. These products are instrumental in hospitals and clinics for accurate patient diagnostics and monitoring, crucial for effective medical decision-making and improved patient outcomes. The company's journey from a modest operation to a global player is a testament to its commitment to research and development, enabling it to produce technologically advanced and reliable products. Fukuda Denshi's revenue model is primarily driven by the sales of its medical devices and systems across various healthcare settings globally. The company continually invests in innovation, ensuring that its products maintain a competitive edge in terms of functionality and reliability. By forming strategic alliances and partnerships, Fukuda Denshi expands its market reach and supports its distribution channels effectively. Additionally, the company provides comprehensive after-sales services, including maintenance and training, ensuring that healthcare providers can optimize the use of its devices. This service component not only enhances customer satisfaction but also establishes long-term relationships, contributing to recurring revenue streams and sustained business growth. Through a business model synergizing product excellence and strategic market engagement, Fukuda Denshi has solidified its position in the healthcare industry, meeting the growing demands for quality medical technology worldwide.
See Also
What is Fukuda Denshi Co Ltd's Total Liabilities?
Total Liabilities
34.4B
JPY
Based on the financial report for Dec 31, 2025, Fukuda Denshi Co Ltd's Total Liabilities amounts to 34.4B JPY.
What is Fukuda Denshi Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
0%
Over the last year, the Total Liabilities growth was 0%. The average annual Total Liabilities growth rates for Fukuda Denshi Co Ltd have been -4% over the past three years , -5% over the past five years .